Published in Ann Rheum Dis on April 01, 2004
Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest (2012) 4.31
Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci (2011) 3.80
Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest (2006) 3.51
Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther (2004) 2.58
Peptidylarginine deiminase 4 contributes to tumor necrosis factor α-induced inflammatory arthritis. Arthritis Rheumatol (2014) 2.14
Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res Ther (2004) 2.05
Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther (2005) 2.03
Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther (2005) 2.02
Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci U S A (2013) 1.98
Hypothesis: the humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis. Inflammation (2004) 1.97
High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis (2006) 1.88
A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med (2013) 1.69
Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med (2009) 1.68
Peptidylarginine deiminase 2, 3 and 4 have distinct specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid arthritis. Ann Rheum Dis (2011) 1.45
Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity. J Biol Chem (2012) 1.45
DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis. Nat Commun (2017) 1.39
PAD4-mediated neutrophil extracellular trap formation is not required for immunity against influenza infection. PLoS One (2011) 1.39
Cigarette Smoke Induces Immune Responses to Vimentin in both, Arthritis-Susceptible and -Resistant Humanized Mice. PLoS One (2016) 1.38
A family based study shows no association between rheumatoid arthritis and the PADI4 gene in a white French population. Ann Rheum Dis (2004) 1.36
Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. J Exp Med (2008) 1.34
Activation of PAD4 in NET formation. Front Immunol (2012) 1.30
Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells. J Exp Med (2011) 1.28
Identification of novel citrullinated autoantigens of synovium in rheumatoid arthritis using a proteomic approach. Arthritis Res Ther (2006) 1.27
Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids. Ann Rheum Dis (2006) 1.27
Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther (2006) 1.24
Porphyromonas gingivalis facilitates the development and progression of destructive arthritis through its unique bacterial peptidylarginine deiminase (PAD). PLoS Pathog (2013) 1.22
Peptidylarginine deiminases in citrullination, gene regulation, health and pathogenesis. Biochim Biophys Acta (2013) 1.20
Identification of PADI2 as a potential breast cancer biomarker and therapeutic target. BMC Cancer (2012) 1.18
Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Res Ther (2008) 1.16
Presence of antibodies against cyclic citrullinated peptides in patients with 'rhupus': a cross-sectional study. Arthritis Res Ther (2006) 1.13
Potential role for peptidylarginine deiminase 2 (PAD2) in citrullination of canine mammary epithelial cell histones. PLoS One (2010) 1.12
Potential role of peptidylarginine deiminase enzymes and protein citrullination in cancer pathogenesis. Biochem Res Int (2012) 1.08
Potential role for PAD2 in gene regulation in breast cancer cells. PLoS One (2012) 1.08
The relevance of citrullinated vimentin in the production of antibodies against citrullinated proteins and the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) (2011) 1.07
The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis (2005) 1.06
PAD4 is not essential for disease in the K/BxN murine autoantibody-mediated model of arthritis. Arthritis Res Ther (2012) 1.06
Bacterial and human peptidylarginine deiminases: targets for inhibiting the autoimmune response in rheumatoid arthritis? Arthritis Res Ther (2010) 1.03
Citrullination of proteins: a common post-translational modification pathway induced by different nanoparticles in vitro and in vivo. Nanomedicine (Lond) (2012) 1.00
Anti-Sa antibodies: prognostic and pathogenetic significance to rheumatoid arthritis. Arthritis Res Ther (2004) 0.98
The expression of PADI4 in synovium of rheumatoid arthritis. Rheumatol Int (2009) 0.98
Current concepts in the pathogenesis of early rheumatoid arthritis. Best Pract Res Clin Rheumatol (2009) 0.97
Local administration of glucocorticoids decreases synovial citrullination in rheumatoid arthritis. Arthritis Res Ther (2012) 0.97
Expression of peptidylarginine deiminase type 4 in ovarian tumors. Int J Biol Sci (2010) 0.94
Polymorphisms in peptidylarginine deiminase associate with rheumatoid arthritis in diverse Asian populations: evidence from MyEIRA study and meta-analysis. Arthritis Res Ther (2012) 0.92
Release of Active Peptidyl Arginine Deiminases by Neutrophils Can Explain Production of Extracellular Citrullinated Autoantigens in Rheumatoid Arthritis Synovial Fluid. Arthritis Rheumatol (2015) 0.91
Detection and quantification of citrullinated chemokines. PLoS One (2011) 0.91
Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullinated histones of NETs. Ann Rheum Dis (2015) 0.90
Dendritic cells, Fc{gamma} receptors, and Toll-like receptors: potential allies in the battle against rheumatoid arthritis. Ann Rheum Dis (2005) 0.88
PAD4 regulates proliferation of multipotent haematopoietic cells by controlling c-myc expression. Nat Commun (2013) 0.87
Peptidylarginine deiminase 2 suppresses inhibitory {kappa}B kinase activity in lipopolysaccharide-stimulated RAW 264.7 macrophages. J Biol Chem (2010) 0.87
Vimentin is involved in peptidylarginine deiminase 2-induced apoptosis of activated Jurkat cells. Mol Cells (2014) 0.86
Citrullinated histone H3: a novel target for the treatment of sepsis. Surgery (2014) 0.86
Citrullination alters immunomodulatory function of LL-37 essential for prevention of endotoxin-induced sepsis. J Immunol (2014) 0.86
Autoantibodies binding to citrullinated telopeptide of type II collagen and to cyclic citrullinated peptides predict synergistically the development of seropositive rheumatoid arthritis. Ann Rheum Dis (2007) 0.85
Transmethylation in immunity and autoimmunity. Clin Immunol (2011) 0.84
Phosphorylation-dependent interaction of tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein (YWHA) with PADI6 following oocyte maturation in mice. Biol Reprod (2008) 0.83
Unlocking the "PAD" lock on rheumatoid arthritis. Ann Rheum Dis (2004) 0.83
Role of anti-citrullinated protein antibodies in diagnosis and prognosis of rheumatoid arthritis. Arch Med Sci (2011) 0.82
NF-Y and Sp1/Sp3 are involved in the transcriptional regulation of the peptidylarginine deiminase type III gene (PADI3) in human keratinocytes. Biochem J (2006) 0.82
PADI2 is significantly associated with rheumatoid arthritis. PLoS One (2013) 0.82
Methods for the detection of peptidylarginine deiminase (PAD) activity and protein citrullination. Mol Cell Proteomics (2013) 0.82
Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma. Leukemia (2016) 0.81
Inhibiting citrullination in rheumatoid arthritis: taking fuel from the fire. Arthritis Res Ther (2012) 0.81
A FluoPol-ABPP PAD2 high-throughput screen identifies the first calcium site inhibitor targeting the PADs. ACS Chem Biol (2014) 0.81
The Role of Posttranslational Protein Modifications in Rheumatological Diseases: Focus on Rheumatoid Arthritis. J Immunol Res (2015) 0.80
Microbial Infection and Rheumatoid Arthritis. J Clin Cell Immunol (2013) 0.80
Crystal structure of Porphyromonas gingivalis peptidylarginine deiminase: implications for autoimmunity in rheumatoid arthritis. Ann Rheum Dis (2015) 0.80
Expression and citrullination of keratin in synovial tissue of rheumatoid arthritis. Rheumatol Int (2009) 0.80
Decreased severity of experimental autoimmune arthritis in peptidylarginine deiminase type 4 knockout mice. BMC Musculoskelet Disord (2016) 0.80
Abrogation of collagen-induced arthritis by a peptidyl arginine deiminase inhibitor is associated with modulation of T cell-mediated immune responses. Sci Rep (2016) 0.79
Protein Arginine Deiminases and Associated Citrullination: Physiological Functions and Diseases Associated with Dysregulation. Curr Drug Targets (2015) 0.79
Potential protein targets of the peptidylarginine deiminase 2 and peptidylarginine deiminase 4 enzymes in rheumatoid synovial tissue and its possible meaning. Eur J Rheumatol (2016) 0.78
Posttranslational Protein Modification in the Salivary Glands of Sjögren's Syndrome Patients. Autoimmune Dis (2013) 0.78
Antibodies to mutated citrullinated vimentin in patients with chronic hepatitis C virus genotype IV infection-related arthropathy. Rheumatol Int (2011) 0.78
Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis. Clin Rheumatol (2010) 0.77
A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy. J Extracell Vesicles (2015) 0.77
The amount of citrullinated proteins in synovial tissue is related to serum anti-cyclic citrullinated peptide (anti-CCP) antibody levels. Clin Rheumatol (2015) 0.77
Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases. Clin Rheumatol (2015) 0.77
Characterization of the Hypercitrullination Reaction in Human Neutrophils and Other Leukocytes. Mediators Inflamm (2015) 0.77
Transcriptomic Segregation of Human Autoantigens Useful for the Diagnosis of Autoimmune Diseases. Mol Diagn Ther (2016) 0.77
PADI4 haplotypes in association with RA Mexican patients, a new prospect for antigen modulation. Clin Dev Immunol (2013) 0.76
Association of anti-CCP positivity with serum ferritin and DAS-28. Rheumatol Int (2009) 0.76
Tumor necrosis factor alpha, citrullination, and peptidylarginine deiminase 4 in lung and joint inflammation. Arthritis Res Ther (2016) 0.76
Anti-Citrullinated Protein Antibodies Induce Macrophage Subset Disequilibrium in RA Patients. Inflammation (2015) 0.75
Anti-cyclic citrullinated peptide antibodies--activity markers in rheumatoid arthritis. J Med Life (2010) 0.75
Inhibition of antithrombin by hyaluronic acid may be involved in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther (2005) 0.75
DNase, ADAMTS13, and iPAD4: good for the heart. Blood (2014) 0.75
Protein Citrullination: A Proposed Mechanism for Pathology in Traumatic Brain Injury. Front Neurol (2015) 0.75
Rheumatoid arthritis antigens homocitrulline and citrulline are generated by local myeloperoxidase and peptidyl arginine deiminases 2, 3 and 4 in rheumatoid nodule and synovial tissue. Arthritis Res Ther (2016) 0.75
The Prerequisites for Central Tolerance Induction against Citrullinated Proteins in the Mouse. PLoS One (2016) 0.75
Pharmacology of intra-articular triamcinolone. Inflammopharmacology (2014) 0.75
Peptidylarginine deiminase 2 is required for tumor necrosis factor alpha-induced citrullination and arthritis, but not neutrophil extracellular trap formation. J Autoimmun (2017) 0.75
GnRH Stimulates Peptidylarginine Deiminase Catalyzed Histone Citrullination in Gonadotrope Cells. Mol Endocrinol (2016) 0.75
Identification of Padi2 as a novel angiogenesis-regulating gene by genome association studies in mice. PLoS Genet (2017) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum (2000) 8.64
Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest (1998) 6.92
Rheumatoid arthritis. Cell (1996) 6.01
How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum (2002) 5.33
PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays (2003) 5.04
The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum (2000) 4.10
A NEW SERUM FACTOR IN PATIENTS WITH RHEUMATOID ARTHRITIS; THE ANTIPERINUCLEAR FACTOR. Ann Rheum Dis (1964) 4.03
mRNA silencing in erythroid differentiation: hnRNP K and hnRNP E1 regulate 15-lipoxygenase translation from the 3' end. Cell (1997) 4.03
Translational control by the 3'-UTR: the ends specify the means. Trends Biochem Sci (2003) 4.00
The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol (2001) 3.92
Anti-keratin antibodies in rheumatoid arthritis. Br Med J (1979) 3.33
Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis (2003) 3.33
Lipoxygenase mRNA silencing in erythroid differentiation: The 3'UTR regulatory complex controls 60S ribosomal subunit joining. Cell (2001) 3.19
A tool coming of age: thapsigargin as an inhibitor of sarco-endoplasmic reticulum Ca(2+)-ATPases. Trends Pharmacol Sci (1998) 2.92
Nuclear localization of peptidylarginine deiminase V and histone deimination in granulocytes. J Biol Chem (2002) 2.78
Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis (2003) 2.53
Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med (2002) 2.53
The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol (1994) 2.44
The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest (1995) 2.37
The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis. J Clin Invest (1993) 2.37
Site-specific phosphorylation induces disassembly of vimentin filaments in vitro. Nature (1987) 2.33
Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res (2001) 2.18
Protein unfolding by peptidylarginine deiminase. Substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin. J Biol Chem (1996) 2.05
Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem (2001) 2.01
HUGE: a database for human large proteins identified in the Kazusa cDNA sequencing project. Nucleic Acids Res (2002) 1.98
Molecular characterization of peptidylarginine deiminase in HL-60 cells induced by retinoic acid and 1alpha,25-dihydroxyvitamin D(3). J Biol Chem (1999) 1.93
Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum (2003) 1.88
Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. Cell Death Differ (2001) 1.87
In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol (2000) 1.77
Deimination of arginine residues in nucleophosmin/B23 and histones in HL-60 granulocytes. Biochem Biophys Res Commun (2002) 1.66
Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res (2000) 1.61
Detection of citrulline residues in deiminated proteins on polyvinylidene difluoride membrane. Anal Biochem (1992) 1.43
Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages. Biochem Biophys Res Commun (1998) 1.42
Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum (2001) 1.42
Regulation of translation by specific protein/mRNA interactions. Biochimie (1994) 1.40
Haploid spermatids exhibit translationally repressed mRNAs. Anat Embryol (Berl) (2001) 1.37
Cleavage of plasma membrane calcium pumps by caspases: a link between apoptosis and necrosis. Cell Death Differ (2002) 1.36
Ca2+-dependent deimination-induced disassembly of intermediate filaments involves specific modification of the amino-terminal head domain. J Biol Chem (1989) 1.36
Immunocytochemical localization of peptidylarginine deiminase in human eosinophils and neutrophils. J Leukoc Biol (2001) 1.36
Diagnosing early-onset rheumatoid arthritis: the role of anti-CCP antibodies. Am Clin Lab (2002) 1.28
Preferential deimination of keratin K1 and filaggrin during the terminal differentiation of human epidermis. Biochem Biophys Res Commun (1996) 1.23
Insights into rheumatoid arthritis derived from the Sa immune system. Arthritis Res (2000) 1.23
Human peptidylarginine deiminase type III: molecular cloning and nucleotide sequence of the cDNA, properties of the recombinant enzyme, and immunohistochemical localization in human skin. J Invest Dermatol (2000) 1.15
Macrophages, synovial tissue and rheumatoid arthritis. Clin Exp Rheumatol (1993) 1.14
cDNA cloning, gene organization and expression analysis of human peptidylarginine deiminase type I. Biochem J (2003) 1.12
Combined biochemical and immunochemical comparison of peptidylarginine deiminases present in various tissues. Biochim Biophys Acta (1988) 1.12
Detection of deiminated proteins in rat skin: probing with a monospecific antibody after modification of citrulline residues. J Invest Dermatol (1995) 1.12
A supramicromolar elevation of intracellular free calcium ([Ca(2+)](i)) is consistently required to induce the execution phase of apoptosis. Cell Death Differ (2002) 1.08
Peptidylarginine deiminase in rat and mouse hemopoietic cells. Experientia (1990) 1.04
Changes in nuclear morphology during apoptosis correlate with vimentin cleavage by different caspases located either upstream or downstream of Bcl-2 action. Genes Cells (1999) 1.04
Human peptidylarginine deiminase type II: molecular cloning, gene organization, and expression in human skin. Arch Biochem Biophys (2002) 1.02
Deimination of 70-kD nuclear protein during epidermal apoptotic events in vitro. J Histochem Cytochem (1998) 1.01
Filaggrin related antibodies among the aged. Ann Rheum Dis (2003) 0.99
Independent regulation of two cytoplasmic processing stages of the intermediate filament-associated protein filaggrin and role of Ca2+ in the second stage. J Biol Chem (1993) 0.97
Changes in vimentin in human macrophages during apoptosis induced by oxidised low density lipoprotein. Atherosclerosis (2001) 0.96
Molecular cloning of cDNAs of mouse peptidylarginine deiminase type I, type III and type IV, and the expression pattern of type I in mouse. Eur J Biochem (1999) 0.93
The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis. Arthritis Rheum (2000) 0.91
Identification of citrulline residues in the V subdomains of keratin K1 derived from the cornified layer of newborn mouse epidermis. Exp Dermatol (1999) 0.91
Rapid release and unusual stability of immunodominant peptide 45-89 from citrullinated myelin basic protein. Biochemistry (1999) 0.90
Immunohistochemical demonstration of peptidylarginine deiminase in human sweat glands. Am J Dermatopathol (1990) 0.88
Isolation and characterization of cDNA clones encoding rat skeletal muscle peptidylarginine deiminase. J Biol Chem (1989) 0.88
Does rheumatoid factor always mean arthritis? Postgrad Med (1993) 0.88
Combined biochemical and immunocytochemical analyses of postmortem protein deimination in the rat spinal cord. Cell Biol Int (1993) 0.84
Peripheral blood monocytes of rheumatoid arthritis patients do not express elevated TNF alpha, IL-1beta, and IL-8 mRNA levels. A comparison of monocyte isolation procedures. J Immunol Methods (1998) 0.83
Antisense-inhibition of plasma membrane Ca2+ pump induces apoptosis in vascular smooth muscle cells. Jpn J Pharmacol (2002) 0.82
Hair follicle peptidylarginine deiminase. Exp Dermatol (1999) 0.79
The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum (2000) 8.64
Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest (1998) 6.92
Identification of the RNA binding segment of human U1 A protein and definition of its binding site on U1 snRNA. EMBO J (1989) 4.69
Major determinants of the specificity of interaction between small nuclear ribonucleoproteins U1A and U2B'' and their cognate RNAs. Nature (1990) 4.67
Polymyositis: an overdiagnosed entity. Neurology (2003) 4.36
The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum (2000) 4.10
cDNA cloning of the human U1 snRNA-associated A protein: extensive homology between U1 and U2 snRNP-specific proteins. EMBO J (1987) 3.47
Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum (2004) 3.38
New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc Natl Acad Sci U S A (1998) 3.14
hnRNA and its attachment to a nuclear protein matrix. J Cell Biol (1981) 2.88
Analysis of a cDNA clone expressing a human autoimmune antigen: full-length sequence of the U2 small nuclear RNA-associated B" antigen. Proc Natl Acad Sci U S A (1987) 2.75
The human U1 snRNP-specific U1A protein inhibits polyadenylation of its own pre-mRNA. Cell (1993) 2.58
Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis (2008) 2.27
The U2B'' RNP motif as a site of protein-protein interaction. EMBO J (1990) 2.12
Cross-linking of mRNA to proteins by irradiation of intact cells with ultraviolet light. Eur J Biochem (1980) 2.04
Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther (2005) 2.03
Human U1 snRNP-specific C protein: complete cDNA and protein sequence and identification of a multigene family in mammals. Nucleic Acids Res (1988) 2.02
The association of the U1-specific 70K and C proteins with U1 snRNPs is mediated in part by common U snRNP proteins. EMBO J (1994) 2.00
Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J Biol Chem (1998) 1.97
Monospecific antibodies reveal details of U2 snRNP structure and interaction between U1 and U2 snRNPs. EMBO J (1986) 1.96
Antibodies against distinct nuclear matrix proteins are characteristic for mixed connective tissue disease. Clin Exp Immunol (1983) 1.92
hPop1: an autoantigenic protein subunit shared by the human RNase P and RNase MRP ribonucleoproteins. EMBO J (1996) 1.87
A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum (1999) 1.85
Characterization of the SS-B (La) antigen in adenovirus-infected and uninfected HeLa cells. EMBO J (1983) 1.83
Analysis of protein--RNA interactions within Ro ribonucleoprotein complexes. Nucleic Acids Res (1991) 1.76
Analysis of heavy and light chain pairings indicates that receptor editing shapes the human antibody repertoire. J Mol Biol (1999) 1.75
Three novel components of the human exosome. J Biol Chem (2000) 1.72
Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin. Ann Rheum Dis (1991) 1.68
In vitro reconstitution of mammalian U1 snRNPs active in splicing: the U1-C protein enhances the formation of early (E) spliceosomal complexes. Nucleic Acids Res (1996) 1.62
Quantitation of anti-RNP and anti-Sm antibodies in MCTD and SLE patients by immunoblotting. Clin Exp Immunol (1985) 1.62
A complex secondary structure in U1A pre-mRNA that binds two molecules of U1A protein is required for regulation of polyadenylation. EMBO J (1993) 1.62
The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol (2000) 1.61
Adenoviral heterogeneous nuclear RNA is associated with the host nuclear matrix during splicing. J Mol Biol (1982) 1.60
U1 small nuclear ribonucleoprotein particle-specific proteins interact with the first and second stem-loops of U1 RNA, with the A protein binding directly to the RNA independently of the 70K and Sm proteins. Mol Cell Biol (1989) 1.56
Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis (2006) 1.54
On the association of mRNA with the cytoskeleton in uninfected and adenovirus-infected human KB cells. Exp Cell Res (1981) 1.48
Scl-86, a marker antigen for diffuse scleroderma. J Clin Invest (1985) 1.43
Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum (2001) 1.42
Specificity in the interaction of hnRNA and mRNA with proteins as revealed by in vivo cross linking. FEBS Lett (1981) 1.42
RNA-protein interactions in the human RNase MRP ribonucleoprotein complex. RNA (1999) 1.41
Familial vs sporadic rheumatoid arthritis (RA). A prospective study in an early RA inception cohort. Rheumatology (Oxford) (2000) 1.41
Conserved amino acid residues within and outside of the N-terminal ribonucleoprotein motif of U1A small nuclear ribonucleoprotein involved in U1 RNA binding. J Mol Biol (1991) 1.40
Independent deposition of heterogeneous nuclear ribonucleoproteins and small nuclear ribonucleoprotein particles at sites of transcription. Proc Natl Acad Sci U S A (1992) 1.40
Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with paediatric- or adult-onset disease. Br J Dermatol (2015) 1.40
Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis (2002) 1.38
[Liver transplantation in patients with HIV infection]. Gastroenterol Hepatol (2004) 1.38
[The anti-synthetase syndrome: muscle disease and multisystem disorder at the same time]. Ned Tijdschr Geneeskd (2003) 1.38
Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann Rheum Dis (2005) 1.35
Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology (Oxford) (2005) 1.34
Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis (2001) 1.34
Differential association of the PTPN22 coding variant with autoimmune diseases in a Dutch population. Genes Immun (2005) 1.32
Ro ribonucleoprotein assembly in vitro. Identification of RNA-protein and protein-protein interactions. J Mol Biol (1992) 1.31
The ribosome cycle in mammalian protein synthesis. II. Association of the native smaller ribosomal subunit with protein factors. J Biol Chem (1973) 1.30
Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann Rheum Dis (2008) 1.28
Somatic insertions and deletions shape the human antibody repertoire. J Mol Biol (1999) 1.28
Architecture and function of the human endonucleases RNase P and RNase MRP. IUBMB Life (2000) 1.25
Subcellular distribution of Ro ribonucleoprotein complexes and their constituents. J Cell Sci (1993) 1.24
Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis (2006) 1.22
Zinc finger-like structure in U1-specific protein C is essential for specific binding to U1 snRNP. Nucleic Acids Res (1991) 1.22
The interactions with Ro60 and La differentially affect nuclear export of hY1 RNA. RNA (1996) 1.21
A weak interaction between the U2A' protein and U2 snRNA helps to stabilize their complex with the U2B" protein. Nucleic Acids Res (1991) 1.21
Ro RNP associated Y RNAs are highly conserved among mammals. Biochim Biophys Acta (1993) 1.19
Methotrexate modulates the kinetics of adenosine in humans in vivo. Ann Rheum Dis (2005) 1.18
hPop5, a protein subunit of the human RNase MRP and RNase P endoribonucleases. J Biol Chem (2001) 1.17
Analysis of in vitro binding of U1-A protein mutants to U1 snRNA. Nucleic Acids Res (1991) 1.17
Intracellular localization and nucleocytoplasmic transport of Ro RNP components. Eur J Cell Biol (1997) 1.17
Analysis of the intracellular localization and assembly of Ro ribonucleoprotein particles by microinjection into Xenopus laevis oocytes. J Cell Biol (1994) 1.16
Alternative splicing pathways exist in the formation of adenoviral late messenger RNAs. J Mol Biol (1983) 1.16
Common structural features of the Ro RNP associated hY1 and hY5 RNAs. Nucleic Acids Res (1994) 1.14
Detection and occurrence of the 60- and 52-kD Ro (SS-A) antigens and of autoantibodies against these proteins. Clin Exp Immunol (1991) 1.14
hPop4: a new protein subunit of the human RNase MRP and RNase P ribonucleoprotein complexes. Nucleic Acids Res (1999) 1.13
The use of immunoblotting to detect antibodies to nuclear and cytoplasmic antigens. Clinical and serological associations in rheumatic diseases. Scand J Rheumatol (1988) 1.13
Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis (2006) 1.12
Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis (1988) 1.11
Rapid nucleolytic degradation of the small cytoplasmic Y RNAs during apoptosis. J Biol Chem (1999) 1.10
Type I interferons might form the link between Toll-like receptor (TLR) 3/7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA). Ann Rheum Dis (2008) 1.10
Specific poly-A-binding protein of 76,000 molecular weight in polyribosomes is not present on poly A of free cytoplasmic mRNP. Nature (1977) 1.09
The La (SS-B) autoantigen, a key protein in RNA biogenesis, is dephosphorylated and cleaved early during apoptosis. Cell Death Differ (1999) 1.09
cDNA cloning and characterization of the human U3 small nucleolar ribonucleoprotein complex-associated 55-kilodalton protein. Mol Cell Biol (1998) 1.07
Comparable heavy and light chain pairings in normal and systemic lupus erythematosus IgG(+) B cells. Eur J Immunol (2000) 1.07
Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blotting. Arthritis Rheum (1997) 1.07
Small nuclear RNA-associated proteins are immunologically related as revealed by mapping of autoimmune reactive B-cell epitopes. Proc Natl Acad Sci U S A (1989) 1.07
Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol (2002) 1.05
Recombinant human antibodies specific for the Pfs48/45 protein of the malaria parasite Plasmodium falciparum. J Biol Chem (2001) 1.04
Characterization of the autoantigen La (SS-B) as a dsRNA unwinding enzyme. Nucleic Acids Res (1997) 1.04
Changes in anti-U1 RNA antibody levels correlate with disease activity in patients with systemic lupus erythematosus overlap syndrome. Arthritis Rheum (1992) 1.04
Topoisomerase I identified by scleroderma 70 antisera: enrichment of topoisomerase I at the centromere in mouse mitotic cells before anaphase. Proc Natl Acad Sci U S A (1986) 1.03
Increased FcgammaRII expression and aberrant tumour necrosis factor alpha production by mature dendritic cells from patients with active rheumatoid arthritis. Ann Rheum Dis (2004) 1.02
Effects of deprival of glucose or individual amino acids on polyribosome distribution and rate of protein synthesis in cultured mammalian cells. Biochim Biophys Acta (1972) 1.02
Multicenter validation of recombinant, natural and synthetic antigens used in a single multiparameter assay for the detection of specific anti-nuclear autoantibodies in connective tissue disorders. Clin Exp Rheumatol (1999) 1.02
Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: citrulline-dependent or not? Ann Rheum Dis (2006) 1.01
Increased expression of CCL18, CCL19, and CCL17 by dendritic cells from patients with rheumatoid arthritis, and regulation by Fc gamma receptors. Ann Rheum Dis (2004) 1.01
Identification of a novel cis-acting RNA element involved in nuclear export of hY RNAs. RNA (2001) 1.01
The La antigen inhibits the activation of the interferon-inducible protein kinase PKR by sequestering and unwinding double-stranded RNA. Nucleic Acids Res (1994) 1.01
Myositis-specific autoantibodies: overview and recent developments. Curr Opin Rheumatol (2001) 1.01